Company Overview - Baolingbao is a leading company in the functional sugar sector, focusing on the research, production, and sales of prebiotics, sugar-reducing sweeteners, and dietary fibers, with an annual comprehensive production capacity exceeding 500,000 tons and over 2,000 active customers [2][3] - The company has recently appointed Mr. Wang Qiang as the general manager, who has extensive management experience in food raw material companies [2] Performance and Growth Strategy - In 2024, Baolingbao is expected to achieve a significant profit increase through proactive adjustments in product structure and marketing strategies, while also adjusting revenue [2] - The company has set ambitious performance targets for 2025-2027, with net profit goals of at least 170 million yuan in 2025, a cumulative total of at least 382 million yuan for 2025-2026, and at least 647 million yuan for 2025-2027 [2] Industry Trends - The functional sugar industry is experiencing rapid growth driven by demographic changes, consumer preferences, and policy guidance, with a shift from traditional sweeteners to healthier alternatives [3] - The demand for sugar substitutes and functional sugars is on the rise, indicating a favorable market environment for Baolingbao's products [3] Product Focus - Baolingbao is the largest producer of isomaltooligosaccharides globally, with prebiotics being the primary source of gross profit in 2024 [4] - The company is also a pioneer in the industrial production of erythritol and is expanding its market share internationally, with erythritol sales revenue increasing by 52.58% year-on-year in 2024 [4] Future Prospects - The company plans to launch several new products utilizing synthetic biology technology in the next 1-2 years, including new capacities for erythritol and a 20,000-ton expansion project for allulose starting in March 2025 [5] - Baolingbao's revenue projections for 2025-2027 are 2.574 billion yuan, 2.794 billion yuan, and 3.069 billion yuan, respectively, with net profits of 170 million yuan, 221 million yuan, and 274 million yuan [5]

公司报告 | 首次覆盖报告 保龄宝（002286） 证券研究报告 功能糖龙头业绩重入增长快轨，未来看点何在？ 1. 保龄宝：功能糖龙头经营策略优化、管理效率提升，24 年业绩重入增长快轨 公司主营益生元、减糖甜味剂、膳食纤维等功能性配料的研产销，年综合产能超 50 万吨，活跃客户超 2000 多家，产品远销 100 多个国家和地区，是中国功能糖领 域的龙头企业。公司通过职业经理人团队管理公司。2023 年 6 月，王强先生被聘 任为公司总经理，拥有丰富的食物原辅料公司管理经验。2024 年，公司通过采取 对产品结构和营销策略的积极调整一系列措施，在营收调整的同时，利润实现显 著增长。2025年公司发布股票激励计划，2025-2027年业绩考核目标分别为：归母 净利润 2025 年不少于 1.7亿元，25-26年累计不少于 3.82 亿元，25-27年累计不少 于 6.47 亿元。25Q1，公司发展延续向好势头。 2. 行业变革：从甜味剂到功能糖，从满足味觉到更健康 功能糖是功能性低聚糖（益生元）、功能性膳食纤维、功能性糖醇（甜味剂）等几 种具有特殊生理功效的物质的统称。从人口结构、消费者偏好、政策指引三个维度 ...

Core Viewpoint - The major shareholder of Baolingbao, Ningbo Baopu Futong Asset Management Center, plans to reduce its stake by up to 3% through block trading and centralized bidding from June 24 to September 23, 2023, despite the company's recent performance recovery [2][7]. Shareholder Reduction - Baolingbao announced that Baopu Futong will reduce its holdings by no more than 3% of the total shares, with a maximum of 2% (7.3953 million shares) through block trading and 1% (3.6977 million shares) through centralized bidding [2][7]. - Since 2020, Baolingbao has disclosed seven announcements regarding Baopu Futong's share reductions, with six plans not executed. The only successful reduction was in July 2020, where 3.85% was reduced from a planned 5.4% [2]. Financial Performance - In 2024, Baolingbao's revenue was approximately 2.402 billion yuan, a decrease of 4.84% year-on-year, primarily due to adjustments in product structure and marketing strategies [4]. - The core business segments, including prebiotics, dietary fiber, and sugar-reducing sweeteners, showed significant recovery, with revenues of approximately 335 million yuan (up 16.02%), 238 million yuan (up 14.52%), and 516 million yuan (up 29.73%) respectively [4]. - In Q1 2025, Baolingbao achieved a revenue of approximately 685 million yuan, a year-on-year increase of 24.23%, and a net profit attributable to shareholders of approximately 50.36 million yuan, up 117.35% [6][7]. Market Dynamics - The European market for Baolingbao's erythritol products has seen an increase in both volume and price following the EU's anti-dumping investigation [5]. - The company is focusing on high-end products such as prebiotics, dietary fiber, and sugar-reducing sweeteners, adopting a business model that emphasizes small-batch, high-value, and differentiated orders [8]. Management Changes - Baolingbao has experienced frequent changes in its executive team, with several high-level resignations in early 2023. Analysts suggest that while some departures may be due to personal reasons, others could relate to operational adjustments [9]. - The competitive landscape for sugar-reducing sweeteners includes major players like Jinhe Industrial and Sanyuan Biological, which have advantages in product development and market channels [9][10]. R&D and Future Outlook - Baolingbao is increasing its investment in allulose, with a technical transformation project set to produce over 5,000 tons annually, and a second-phase expansion project planned for 20,000 tons [10]. - Despite the growth in the sugar-reducing sweetener market, industry analysts express caution regarding the pace of product innovation and the competitive gap between Baolingbao and leading companies [10].

Market Outlook - The market for health-conscious products is expected to grow significantly due to rising income levels and changing consumer preferences towards sugar-free and nutritious options [2] - The aging population presents a substantial opportunity in the silver economy, with increasing demand for health improvement products [2] - National policies are anticipated to further boost the market for natural sweeteners and functional health foods such as prebiotics and dietary fibers [2] Revenue Projections - The company aims for a net profit of no less than 170 million RMB in 2025 as part of its stock incentive plan [6] - The company expects stable growth in its three core products: prebiotics, dietary fibers, and sugar-reducing sweeteners [4] Production Capacity - The company has initiated a project to expand its production capacity of allulose to 20,000 tons annually, with an expected total capacity of approximately 30,000 tons by 2026 [3] - The company has completed the construction of a 2,500-ton annual production line for HMOs (human milk oligosaccharides) and is currently in the trial production phase [6] Impact of Raw Material Prices - The company is closely monitoring corn prices and employing strategies to balance procurement costs and market uncertainties [3] Export and Market Expansion - The company plans to establish a sales subsidiary in the U.S. and enhance customer service to increase market share [7] - The company’s export business to the U.S. is expected to benefit from reduced tariffs, which will facilitate exports [4] Industry Trends - The overall industry is benefiting from the growing health consciousness among consumers and the aging population, which is driving demand for health-related products [11] - The company’s market share for erythritol in the EU has increased to 50%, with a significant revenue growth of approximately 123% year-on-year in Q1 2025 [5] Stock Performance and Investor Relations - The company is actively engaging in investor relations to improve market perception and stock performance, including hosting analyst meetings and enhancing information disclosure [10] - The company acknowledges that stock price is influenced by various factors, including company earnings and market conditions [12]

证券研究报告 | 公司深度 | 农产品加工 保龄宝(002286) 报告日期：2025 年 05 月 08 日 产品结构优化驱动盈利改善，功能糖龙头再谱新篇章 ——保龄宝深度报告 投资要点 ❑ 要点一 引入职业经理人助力公司改革，产品结构优化驱动盈利改善。公司成立于 1997 年，是国内功能糖和营养补充剂产品矩阵最为丰富的企业之一，公司现已构成由 淀粉糖—减糖甜味剂—益生元—膳食纤维—特种功能性食品原料的五层产品矩 阵。在经历了 2019 年赤藓糖醇爆火后的冲高回落，公司在管理层中引入职业经 理人，在行业下行期积极调整经营策略和产品结构，在优化成本的同时推出高附 加值及差异化产品，助力公司去年实现利润的触底反弹，毛利率得到显著改善。 ❑ 要点二 赤藓糖醇反倾销受益标的，关注阿洛酮糖国内增量市场。赤藓糖醇在经历 21 年 元气森林爆火后，随着新增产能投产，价格冲高回落至景气度底部，当前行业格 局趋于稳定，全球仅中国、欧洲和美国拥有产能，公司目前拥有 3 万吨/年的产 能，受益于公司是欧盟反倾销税率最低的国内企业，预计公司赤藓糖醇在欧洲市 场有望迎来量价齐升，根据我们的测算，公司在欧洲的边际最优定价为 1.58 ...

Group 1 - The company has introduced professional managers to assist in reform and optimize product structure, leading to improved profitability. The company, established in 1997, has a diverse product matrix in functional sugars and nutritional supplements, consisting of five layers: starch sugars, reduced-sugar sweeteners, prebiotics, dietary fibers, and special functional food ingredients. After the peak and subsequent decline of erythritol in 2019, the company adjusted its operational strategies and product structure during the industry downturn, resulting in a significant rebound in profits and gross margin improvement last year [1] - Erythritol is benefiting from anti-dumping measures, and there is a focus on the domestic market potential for allulose. Following the surge in popularity of erythritol in 2021, prices have stabilized at a low point due to new production capacities. The company has an annual capacity of 30,000 tons and is the domestic enterprise with the lowest anti-dumping tax rate in the EU, which is expected to lead to a rise in both volume and price in the European market. The optimal marginal pricing for the company in Europe is estimated at 15,800 yuan per ton, higher than the domestic price of 6,500 yuan per ton. Additionally, the U.S. has initiated a "double anti" investigation against Chinese erythritol, with preliminary anti-dumping tax rates set at 260%-450%. The company is not a mandatory respondent, and attention should be paid to the market changes in the U.S. following the May tax rate announcement. Allulose, as a new star in the sugar substitute market, has significant growth potential, with domestic approval expected in March [1][2] Group 2 - In 2024, all major segments of the company achieved growth in both sales and gross margin, with stock incentives reflecting confidence in future development. The company reported a net profit attributable to shareholders of 111 million yuan in 2024, a year-on-year increase of 106%. The growth was driven by increased sales and gross margins across key revenue segments, with sales volumes for prebiotics, dietary fibers, reduced-sugar sweeteners, starch sugars, and others reaching 357,000 tons, 214,000 tons, 500,000 tons, and 2,426,000 tons, respectively, representing year-on-year growth of 23.74%, 14.39%, 41.66%, and 2.29%. Gross margins for these segments were 24.60%, 18.12%, 9.09%, and 12.22%, with year-on-year increases of 5.26 percentage points, 5.48 percentage points, 7.83 percentage points, and 2.17 percentage points. The company announced stock incentives for 2024, with performance targets for 2025-2027 set at 170 million yuan, 212 million yuan, and 265 million yuan, corresponding to growth rates of 53%, 25%, and 25%, demonstrating confidence in future development [2] Group 3 - Profit forecasts and valuations indicate that the company is expected to achieve net profits attributable to shareholders of 181 million yuan, 216 million yuan, and 260 million yuan from 2025 to 2027, with corresponding PE valuations of 20.07, 16.82, and 13.99 times. The initial coverage has been initiated with a "buy" rating [3]

21世纪经济报道记者贺泓源、实习生谭伊亭 报道 中国制造的韧性体现在多个方面。 保龄宝在近期披露的机构交流纪要中透露，随着欧盟对赤藓糖醇征收反倾销税后，该公司相关产品在欧 洲地区反而实现量价齐升。 "2025年1月16日，欧盟委员会公布了关于本次赤藓糖醇反倾销调查终裁公告，对国内赤藓糖醇生产企业 征收34.4%-233.3%不等的反倾销税。上述反倾销措施于欧盟终裁公告发布次日（即2025年1月17 日）起 生效，实施期限为5年。其中，保龄宝相关产品被征收 34.4%的反倾销税，为本次反倾销加征税率最低 的企业。公司抓住反倾销税率最低带来的市场机遇，赤藓糖醇产品在欧洲地区实现量价齐升，良好的国 际影响力和品牌力也带动了国内销售。受此影响，2025年一季度，公司赤藓糖醇销售收入同比增长约 123%。"保龄宝如此解释。 此外，保龄宝还提到，其对美出口收入占公司总体收入比例不算很高， 从一季度实际发货情况来看， 不存在突击发货的现象。"有个别客户订单量有所增加，对整体发货量也影响有限，且2025年一季度公 司产品美国发货量与年初预算基本相符。"该公司表示。 财报显示，在2024年，保龄宝营收同比下滑4.84%至24. ...

证券之星消息，2025年4月30日保龄宝（002286）发布公告称公司于2025年4月29日召开分析师会议，浙 商证券（601878）石化分析师邹骏程、方正证券食品饮料分析师谌保罗、华泰柏瑞基金管理有限公司丁 续、大成基金管理有限公司刘芳琳、摩根基金管理(中国)有限公司刘健、交银施罗德基金管理有限公司 张明晓、路博迈基金管理(中国)有限公司谢楠、海富通基金管理有限公司踪敬珍、西部利得基金管理有 限公司张昭君陈雨、中邮创业基金管理股份有限公司綦征、嘉合基金管理有限公司曹瀚允、国泰海通证 券基础化工分析师周志鹏、招商基金于凡真、金信基金管理有限公司龙毅、宁波盛世知己投资管理中心 (有限合伙)王小刚、安信证券资产管理有限公司王炳修、杭州巨子私募基金管理有限公司张立烽、湖南 源乘私募基金管理有限公司邬安沙、武汉证国私募陈阜东、中债信用增进投资股份有限公司郑倩、 PleiadInvestmentAdvisorsLimited孫洋、上海云门投资管理有限公司俞忠华、信达证券（601059）食品饮 料分析师赵雷、上海途灵资产管理有限公司赵梓峰、华安证券（600909）化工新材料分析师刘天其、中 信建投（601066）证券食品 ...

| 上市公司接 | 总经理 王强 | | --- | --- | | 待人员姓名 | 董事会秘书 朱哲 | | | 财务总监 周瑜 | | | 董事会秘书首先向与会机构代表介绍公司基本情况及 2024 年年度和 2025 | | | 年一季度经营情况。 | | | 公司主要从事益生元、膳食纤维、减糖甜味剂等功能性配料的研发、生产、 | | | 销售，系国内功能糖首家产业化生产企业和上市公司，致力于成为全球功能配料 | | | 与健康食品创新的引领者。公司布局食品营养、口感和质构改善以及医药原辅料 | | | 三大业务领域。食品营养领域主要产品为益生元、膳食纤维、减糖甜味剂等，口 | | | 感和质构改善领域主要以变性淀粉为主，医药原辅料领域主要为药用乳果糖、药 | | | 用赤藓糖醇等。 | | | 公司已形成淀粉、淀粉糖、减糖甜味剂、膳食纤维、益生元、药用糖（醇） | | | 等的全产业链制造体系和自下而上附加值逐步提升的产品金字塔矩阵，可满足下 | | | 游客户"多品种、差异化、全方位"采购需求。 | | 投资者关系 | 2024 年度，公司实现归属于上市公司股东的净利润 11,115.98 万元，同比 ...

近日，保龄宝生物股份有限公司（002286.SZ，以下简称"保龄宝"）发布2024年年度。报告显示，2024年，保龄宝实现营收24.02亿元，同比下滑4.84%；净 利润为1.11亿元，同比大增105.97%；扣非净利润为1.24亿元，同比增长254.56%。 保龄宝利润大幅增长的关键在于高附加值产品的销量提升和成本端的有效控制。 2024年，保龄宝益生元、膳食纤维和减糖甜味剂三大核心业务因满足了消费者对于健康食品、饮料的需求，实现了快速增长，2024年营收同比分别增长 16.02%、14.52%和29.73%。其中，赤藓糖醇销售收入同比增长52.58%，主要得益于欧盟反倾销政策落地后，保龄宝以34.4%的最低税率成功抢占欧洲市场。 2024年，保龄宝通过优化供应链管理，降低玉米、玉米淀粉等原材料采购成本，并改进生产工艺，使得整体毛利率同比提升3.78个百分点至11.88%。 研发创新是保龄宝的另一大亮点，2024年研发投入占比提升至4.08%，研发团队规模扩大至154人，高学历人才占比显著提高。2025年3月，保龄宝凭借"高 纯度母乳低聚糖舒慕滋"技术斩获食品界"诺贝尔奖"iSEE全球创新奖，进一步巩固了其 ...